22

A look at the world endocrinology market

At a value of $US8.5 billion, the endocrinology market comprises around 6% of the world's total pharmaceutical market, reports Dalamon;lor [7 Nov]. Sales are greatest for the endocrine agents used to treat chronic conditions such as diabetes and the menopause [see figure].

Worldwide sales of endocrine drugs in 1993

• a.nlgn p,oallllic hypenroplly

In 1993, the antihyperglycaemic agents Novolin® [Novo-Nordisk] and Humulin® [Eli Lilly] achieved worldwide sales of $US878 million and $650 million, respectively. Humulin was the most prescribed antihyperglycaemic in the US, while Novolin® was the most prescribed insulin therapy in Europe. The postmenopausal hormone replacement product Premarin® [American Home Products] achieved worldwide sales of $749 million in 1993; it was the most prescribed endocrine drug in the US in terms of volume. The predicted sales of Novolin®, Humulin® and Premarin® for the year 2002 are $1250 million, $900 million and $1250 million, respectively.

Rapid growth of the osteoporosis market is likely to occur following the approval of bisphosphonates for this condition in major markets, forecasts Dalamonilor. The hormone replacement market is also likely to increase by the year 2000, driven by the shift in perception of the menopause. In contrast, the US human growth hormone market will be affected by the allegations of inefficacious drugs and over­screening of children. -Media release

12 Nov 1l1li4 INPHARMA- 0156·270319410963-000221$01 .00° Adl. International Limited ,l1li4. All rlghta ~